ZERVIATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZERVIATE (ZERVIATE).
ZERVIATE (cetirizine ophthalmic solution) contains cetirizine, a selective histamine H1 receptor antagonist. It inhibits histamine-induced vasodilation and increased vascular permeability, leading to reduction of ocular itching associated with allergic conjunctivitis.
| Metabolism | Cetirizine is primarily metabolized via oxidative metabolism, but to a limited extent; the major metabolic pathway is through CYP3A4, but it is not extensively metabolized. Excretion occurs mainly via renal elimination. |
| Excretion | Primarily renal excretion of unchanged drug (approximately 70%) and metabolites; biliary/fecal elimination accounts for less than 20%. |
| Half-life | Terminal elimination half-life is approximately 3 hours; clinical context: supports twice-daily topical ocular dosing for allergic conjunctivitis. |
| Protein binding | Approximately 40% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is 1.4 L/kg; indicates extensive distribution into body tissues beyond plasma volume. |
| Bioavailability | Ophthalmic solution: Systemic bioavailability is very low (less than 10%) due to limited absorption through the conjunctiva and corneal epithelium. |
| Onset of Action | Ophthalmic administration: Onset of clinical effect is within 15 minutes for relief of ocular itching. |
| Duration of Action | Duration of action is up to 8 hours for symptom relief; clinical notes: requires twice-daily administration for sustained effect. |
1 drop in each affected eye twice daily (approximately 8 hours apart).
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Children 2 years and older: same as adult dose. Safety and efficacy in children below 2 years not established. |
| Geriatric use | No specific dose adjustment required; use same as adult dose. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ZERVIATE (ZERVIATE).
| Breastfeeding | No human data on presence in breast milk, effects on breastfeeding infant, or milk production. Based on low systemic absorption, likely minimal exposure. Caution advised; consider developmental benefits of breastfeeding vs. potential risk of anticholinergic effects (antihistamine class). M/P ratio: not determined. |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. Animal studies: No evidence of teratogenicity in rats at ocular doses up to 1 mg/kg/day (systemic exposure ~750 times the maximum recommended human ocular dose). However, systemic absorption is minimal (mean Cmax ~0.1 ng/mL). Potential risk to fetus cannot be ruled out; use only if clearly needed. First trimester: risks unknown; second and third trimesters: no specific risks identified but limited data. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to any component of the product or to hydroxyzine or any piperazine derivative.
| Precautions | ["To minimize contamination, do not touch the dropper tip to any surface.","Contact lenses should be removed prior to instillation and may be reinserted after 10 minutes.","Not for injection; for topical ophthalmic use only."] |
Loading safety data…
| Fetal Monitoring | No specific monitoring required beyond standard prenatal care. Monitor for maternal ocular adverse effects; no fetal monitoring indicated due to minimal systemic exposure. |
| Fertility Effects | No studies on fertility in humans. Animal studies: No impairment of fertility in rats at oral doses up to 100 mg/kg/day (systemic exposure ~75,000 times MROHD). Based on low systemic absorption, no expected effect on human fertility. |